Navigation Links
Nature's Bioceuticals Finalizes The Purchase of Cold and Flu Formula
Date:11/10/2011

CAPE CORAL, Fla., Nov. 10, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures, Inc. (MILV.pk - News) announced that it has executed the closing documents for the purchase of the cold and flu formula and now has the exclusive rights to the formula.

The common cold, an infection of the upper respiratory tract, is caused by any of 200 different viruses. The viral infection and the immune system's battle against it produce the all-too-familiar symptoms: sore throat, nasal congestion, runny nose, watery eyes, hacking cough and sometimes fever. It is a viral infection, so things like antibiotics, which are often mistakenly prescribed for colds, won't help. Giving antibiotics for viral diseases is a distressingly common practice. Studies have shown that 60 percent of patients who went to the doctor with one of the viruses that cause the common cold received an inappropriate prescription for antibiotics.

Sales of cold and flu formulas slipped slightly between 2009 and 2010, down 1.2% for sales of $3.8 billion. Helping to decelerate the losses was both competitive threats from alternative remedies and increased sales of private label products across all segments of the market, as consumers sought out more affordable remedies during the poor economy, often with the view that these medicines work just as well as national brands. However, most of these products simply mask the symptoms and do little or nothing to address attacking the cause. Many people have lost confidence in OTC products due to bad press, a number of recalls and FDA recommendations. Further, on March 2, 2011 the FDA announced steps to remove more than 500 prescription cold, cough, and allergy products from the market because of potential safety concerns.  The FDA asked companies to stop manufacturing the 500 products within 90 days and stop shipping them within 180 days. Some manufacturers were required to stop making and shipping their products immediately.

Robert deZanger, CEO of Natures Bioceuticals stated, "We are pleased to add this spectacular natural medicine to our existing product line. Although the Cold and Flu market is flooded with a number of established brands, we are confident that we can capture a significant portion of the market with an all natural product that really works. The goal we have set is to capture 3% of the US market within a 3 year period, which could possibly generate over $100,000,000 in revenues for the company.  Our formula contains over twenty different herbs that are all 'active ingredients'. The formula provides relief from the cold and flu symptoms, but more importantly, it boosts the body's immune response to combat the cause of the virus. When taken at the onset of symptoms the formula has shown the ability to reduce the severity and duration of a cold or flu. It has also in many cases arrested the virus before symptoms are able to come to fruition. The inventor has for many years been conducting research to find a 'cure' for the common cold. This formula was invented as a result of that ongoing research. We now intend to hire an independent testing group to do a clinical trial(s) to formally document the results we have achieved and publish a report for the medical community."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA".

In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com


'/>"/>
SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
2. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
3. Natures Bioceuticals Tears Into the Multi-Billion Dollar Chronic Kidney Disease Market
4. FDA Finalizes Regulation For Certain Software, Hardware Used With Medical Devices
5. Scott & White Finalizes College Station Land Deal
6. Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd.
7. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
8. Mindray Announces Up to $100 Million Share Repurchase Program
9. Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program
10. Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase
11. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... TAMPA, Fla. , Feb. 22, 2017  Corin ... Shoulder System, a device used to treat patients with ... form of shoulder arthritis. The condition, known as cuff ... arm and shoulder. The Humelock Reversed ... privately-held upper extremities technology company based near ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Pipeline Review, 2016" report to their offering. ... Dermatological conditions ... and approximately one-third of the US population suffers from at ... majority of the dermatology market has remained saturated with established ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
Breaking Medicine Technology:
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine ... a small number of neurosurgeons in Michigan performing minimally invasive back surgery that ...
(Date:2/22/2017)... ... ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: The ... PM ET. A recording of the webinar will also be made available following its ... want to find out what really happened in the seniors housing and care merger ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
(Date:2/22/2017)... OAKLAND/SAN FRANCISCO BAY AREA - NORTHERN CALIFORNIA (PRWEB) , ... ... ... Forum (PMF) aims to expand the pipeline and the number of African ... support that encourages medical students and residents to pursue their careers as physicians ...
Breaking Medicine News(10 mins):